sns-314
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00519662)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Serine/threonine-protein kinase Aurora inhibitor
Pan-Aurora kinase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(Nc1cccc(Cl)c1)Nc1ncc(CCNc2ncnc3ccsc23)s1- Mol. weight
- 430.95 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL482767 ↗
Also known as
- sns314
- sns 314
- sns-314
- sns-314
- sns-314
- sns-314
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00519662 | Phase 1 | Aug 1, 2007 | Sunesis Pharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunesis Pharmaceuticals | For profit | 1 | 1 | 1 | 2007 |
1 organizations
Page 1 / 1